I can't recall if this discussion was put to bed, but when talking about the M-Enoxaparin multiple generics scenario, Shea said something to the effect of "In the case of other interchangeable generics, Momenta would receive a high single or low double digit royalty".
In other words, the discussion of substitutible vs non-substituble Lovenox in the case of Teva and other competitors is very pertinent to Momenta's partnership agreement with Sandoz/Novartis.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.